Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Trends in Cancer|March 4, 2026
FGFR rearrangements: oncogenic drivers and therapeutic targetsJulia Yemelyanenko, Jos Jonkers, Daniel ZinggBiochimica Et Biophysica Acta. Reviews on Cancer|March 3, 2020
Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disordersKarlijn van Loon, Julia Yemelyanenko-Lyalenko, Coert Margadant, et al.Oncoimmunology|March 3, 2020
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune systemSjoerd Klarenbeek, Chris W Doornebal, Sjors M Kas, et al.Cancer Research|December 29, 2025
C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3Julia Yemelyanenko, Jinhyuk Bhin, Eline van der Burg, et al.Cancer Research|June 24, 2025
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2Daniel Zingg, Chi-Chuan Lin, Julia Yemelyanenko, et al.The Journal of Experimental Medicine|August 29, 2023
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancerJinhyuk Bhin, Julia Yemelyanenko, Xue Chao, et al.Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.Pageof 1